惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

H
Help Net Security
腾讯CDC
爱范儿
爱范儿
Google DeepMind News
Google DeepMind News
V
V2EX
Blog — PlanetScale
Blog — PlanetScale
Engineering at Meta
Engineering at Meta
GbyAI
GbyAI
量子位
F
Fortinet All Blogs
G
Google Developers Blog
T
The Blog of Author Tim Ferriss
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
Hugging Face - Blog
Hugging Face - Blog
Last Week in AI
Last Week in AI
T
Tailwind CSS Blog
J
Java Code Geeks
S
SegmentFault 最新的问题
D
Docker
博客园 - 司徒正美
The GitHub Blog
The GitHub Blog
Jina AI
Jina AI
M
MIT News - Artificial intelligence
博客园 - 【当耐特】

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Croda International Plc (COIHY) Q1 2026 Sales/Trading Cal...
2026-04-24 · via All Articles on Seeking Alpha

Croda International Plc (COIHY) Q1 2026 Sales/Trading Call April 22, 2026 2:30 AM EDT

Company Participants

Steve Foots - Group Chief Executive & Executive Director
Stephen Oxley - CFO & Executive Director

Conference Call Participants

Matthew Yates - BofA Securities, Research Division
Charles Eden - UBS Investment Bank, Research Division
Katie Richards - Barclays Bank PLC, Research Division
Ming Tang - BNP Paribas, Research Division
Sebastian Bray - Joh. Berenberg, Gossler & Co. KG, Research Division
Artem Chubarov - Rothschild & Co Redburn, Research Division
Lisa Hortense De Neve - Morgan Stanley, Research Division
Chetan Udeshi - JPMorgan Chase & Co, Research Division
Georgina Iwamoto - Goldman Sachs Group, Inc., Research Division
Ranulf Orr - Citigroup Inc., Research Division

Presentation

Operator

Hello, and welcome to the Croda International Q1 2026 Sales Update Call. Please note, this call is being recorded. [Operator Instructions]

I will now hand you over to your host, Steve Foots, to begin today's conference. Please go ahead, sir.

Steve Foots
Group Chief Executive & Executive Director

Good morning, everyone. Many thanks for joining. So I'm here with Stephen and David, and together, happy to take your questions.

So first, just a few overview comments from me. Overall, quarter 1 sales were as we expected it, up 1% at constant currency and similar to a very strong quarter last year. And whilst we acknowledge the heightened uncertainty that the Middle East conflict has caused, it had no material effect on quarter 1, and there is no change to guidance for full year '26.

So breaking our quarter 1 sales performance down by business, sales were up 4% in Consumer Care, driven by Beauty Actives and F&F. Life Sciences saw sales dip 3%, largely due to Crop Protection being 8% lower versus a strong prior year when we saw significant restocking. And industrial sales were down 2%, again against a strong prior period.